Drugs / IMC-002
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07266311 | Dec 2025 → Dec 2035 expected | — | Chengdu Ucello Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05946226 | Sep 2023 → Dec 2025 | digestive system neoplasm | Suzhou Immunofoco Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05472857 | Aug 2022 → Dec 2024 | gastric cancer, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm, ovarian carcinoma | Suzhou Immunofoco Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05276310 | Jun 2022 → Dec 2027 expected | — | ImmuneOncia Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04306224 | Jun 2020 → Oct 2022 | cancer, lymphoma | ImmuneOncia Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06535412 | Oct 2024 → Dec 2028 expected | systemic lupus erythematosus | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06557174 | Oct 2024 → Nov 2025 overdue | neuromyelitis optica | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04306224 ↗ |
| Known as | Claudin 18.2 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05472857 ↗ |
| Action | Inhibit | “IMC-002 blocks the interaction between CD47 and SIRPα.” NCT04306224 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cell therapy” NCT05472857 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05276310 ↗ |
| Target | CLDN18 | “CLDN18.2-targeting CAR T Cells” NCT05472857 ↗ |